Bloom Burton Issues Pessimistic Outlook for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Bloom Burton lowered their Q3 2025 EPS estimates for shares of Medexus Pharmaceuticals in a report released on Monday, November 11th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their previous estimate of $0.07. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.19 EPS, FY2026 earnings at $0.18 EPS and FY2027 earnings at $0.13 EPS.

A number of other research analysts also recently weighed in on the company. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Finally, Stifel Nicolaus boosted their target price on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$2.03 on Wednesday. The company’s 50 day simple moving average is C$2.52 and its 200 day simple moving average is C$2.18. Medexus Pharmaceuticals has a fifty-two week low of C$1.44 and a fifty-two week high of C$3.16. The firm has a market capitalization of C$49.80 million, a P/E ratio of 40.60 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.